IFRX
Price
$1.75
Change
+$0.15 (+9.38%)
Updated
Sep 2 closing price
Capitalization
118.56M
57 days until earnings call
PRTA
Price
$8.27
Change
+$0.07 (+0.85%)
Updated
Sep 2 closing price
Capitalization
445.17M
57 days until earnings call
Interact to see
Advertisement

IFRX vs PRTA

Header iconIFRX vs PRTA Comparison
Open Charts IFRX vs PRTABanner chart's image
InflaRx
Price$1.75
Change+$0.15 (+9.38%)
Volume$2.59M
Capitalization118.56M
Prothena
Price$8.27
Change+$0.07 (+0.85%)
Volume$1.05M
Capitalization445.17M
IFRX vs PRTA Comparison Chart in %
Loading...
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IFRX vs. PRTA commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IFRX is a StrongBuy and PRTA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (IFRX: $1.60 vs. PRTA: $8.20)
Brand notoriety: IFRX and PRTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IFRX: 989% vs. PRTA: 86%
Market capitalization -- IFRX: $118.56M vs. PRTA: $445.17M
IFRX [@Biotechnology] is valued at $118.56M. PRTA’s [@Biotechnology] market capitalization is $445.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $102.81B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IFRX’s FA Score shows that 0 FA rating(s) are green whilePRTA’s FA Score has 0 green FA rating(s).

  • IFRX’s FA Score: 0 green, 5 red.
  • PRTA’s FA Score: 0 green, 5 red.
According to our system of comparison, PRTA is a better buy in the long-term than IFRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IFRX’s TA Score shows that 5 TA indicator(s) are bullish while PRTA’s TA Score has 2 bullish TA indicator(s).

  • IFRX’s TA Score: 5 bullish, 5 bearish.
  • PRTA’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, IFRX is a better buy in the short-term than PRTA.

Price Growth

IFRX (@Biotechnology) experienced а +75.15% price change this week, while PRTA (@Biotechnology) price change was -6.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

IFRX is expected to report earnings on Oct 30, 2025.

PRTA is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRTA($445M) has a higher market cap than IFRX($119M). IFRX YTD gains are higher at: -35.223 vs. PRTA (-40.794). IFRX has higher annual earnings (EBITDA): -44.6M vs. PRTA (-248.1M). PRTA has more cash in the bank: 371M vs. IFRX (48M). IFRX has less debt than PRTA: IFRX (599K) vs PRTA (9.78M). PRTA has higher revenues than IFRX: PRTA (10.3M) vs IFRX (163K).
IFRXPRTAIFRX / PRTA
Capitalization119M445M27%
EBITDA-44.6M-248.1M18%
Gain YTD-35.223-40.79486%
P/E RatioN/AN/A-
Revenue163K10.3M2%
Total Cash48M371M13%
Total Debt599K9.78M6%
FUNDAMENTALS RATINGS
IFRX vs PRTA: Fundamental Ratings
IFRX
PRTA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3646
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRTA's Valuation (56) in the Biotechnology industry is in the same range as IFRX (70). This means that PRTA’s stock grew similarly to IFRX’s over the last 12 months.

PRTA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IFRX (100). This means that PRTA’s stock grew similarly to IFRX’s over the last 12 months.

PRTA's SMR Rating (98) in the Biotechnology industry is in the same range as IFRX (98). This means that PRTA’s stock grew similarly to IFRX’s over the last 12 months.

IFRX's Price Growth Rating (36) in the Biotechnology industry is in the same range as PRTA (46). This means that IFRX’s stock grew similarly to PRTA’s over the last 12 months.

PRTA's P/E Growth Rating (94) in the Biotechnology industry is in the same range as IFRX (100). This means that PRTA’s stock grew similarly to IFRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IFRXPRTA
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bullish Trend 5 days ago
80%
Bearish Trend 5 days ago
85%
MACD
ODDS (%)
Bullish Trend 5 days ago
78%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
81%
Bearish Trend 5 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 12 days ago
75%
Declines
ODDS (%)
Bearish Trend 26 days ago
86%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
77%
Aroon
ODDS (%)
Bearish Trend 5 days ago
84%
Bullish Trend 5 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CREYX9.920.06
+0.61%
Columbia Real Estate Equity Inst3
RYAEX120.61-0.41
-0.34%
Rydex Europe 1.25x Strategy A
ITRGX69.30-0.88
-1.25%
VY® T. Rowe Price Growth Equity S2
CTSOX43.62-0.57
-1.29%
Calamos Timpani Small Cap Growth R6
PRGTX24.28-0.43
-1.74%
T. Rowe Price Global Technology

IFRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IFRX has been loosely correlated with PRTA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if IFRX jumps, then PRTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IFRX
1D Price
Change %
IFRX100%
+36.75%
PRTA - IFRX
34%
Loosely correlated
-0.49%
RCUS - IFRX
28%
Poorly correlated
-0.19%
VERA - IFRX
28%
Poorly correlated
-2.92%
NMRA - IFRX
26%
Poorly correlated
-1.70%
ARWR - IFRX
26%
Poorly correlated
-1.39%
More

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with RCKT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
-0.49%
RCKT - PRTA
51%
Loosely correlated
-2.09%
SVRA - PRTA
46%
Loosely correlated
+0.31%
DNLI - PRTA
39%
Loosely correlated
-2.43%
OCUL - PRTA
36%
Loosely correlated
-2.48%
NUVB - PRTA
35%
Loosely correlated
+1.71%
More